ClinicalTrials.gg
Status unknownNCT04868253Updated May 28, 2021

Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment

A Phase 2/3 interventional study of EMB-01 in Smoking Cessation and Tobacco Use Disorder, sponsored by Rose Research Center, LLC. Status unknown at 1 site in United States. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-28.

Sponsored by Rose Research Center, LLC · Phase 2/3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Smoking Cessation by Rose Research Center, LLC — none open to participants now, none under way, none of them phase 3. Smoking Cessation · Rose Research Center, LLC.

Planned enrollment
6th of 10
25 · median 26
Started
2021
with 1 other
Phase 2/3
2 of 10
none open now
Registered
5th of 10
by date

Among the 10 studies in Smoking Cessation by Rose Research Center, LLC, this one is the 6th largest by planned enrollment, is one of 2 that started in 2021, is one of 2 in phase 2/3, and was the 5th registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

None of the 10 studies in Smoking Cessation by Rose Research Center, LLC is open now. The open studies under Smoking Cessation, anywhere →

Where they have run

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Smoking Cessation by Rose Research Center, LLC as a file.
02

Study summary

This open-label study will evaluate EMB-001, comprised of metyrapone, a cortisol synthesis inhibitor marketed as a diagnostic drug for testing hypothalamic-pituitary-adrenal (HPA) axis function, combined with oxazepam, an anxiolytic and sedative/hypnotic benzodiazepine, to help smokers abstain from smoking during a 12-week trial period.

03

Conditions studied

  • Smoking Cessation
  • Tobacco Use Disorder
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has signed the ICF and is able to read and understand the information provided in the ICF.
  2. Healthy smokers 21 to 65 years of age (inclusive) at screening.
  3. Smokes an average of at least 10 commercially available cigarettes per day for the last 12 months.
  4. Has an expired air CO reading of at least 10 ppm at screening.
  5. Express a desire to quit smoking within the next 30 days at screening.
  6. Serum Cortisol > 3 μg/dL at screening.
  7. Willing and able to comply with the requirements of the study.
  8. Owns a smart phone with text message and data capabilities compatible with necessary surveys.

Exclusion criteria

Exclusion Criteria:

  1. Is unhealthy or cannot participate in the study for any reason (e.g., medical, psychiatric, and/or social reason) as judged by the Investigator or designated medical staff based on all available assessments from the screening period (e.g., safety laboratory, vital signs, physical examination, , concomitant medications and medical history).
  2. PHQ-9 score greater than 9, or a score greater than 0 on item #9.
  3. Elevated (AST) or alanine aminotransferase (ALT) greater than two times the or history of liver disease.
  4. Have positive serology test results for (HIV)-1/HIV-2 antibodies, surface antigen, or antibody.
  5. High blood pressure (systolic > 150 mmHg or diastolic >95 mmHg) at screening.
  6. (BMI) less than 18.5 kg/m2 or greater than 35.0 kg/m2.
  7. Coronary heart disease, structural cardiac disease, cardiac dysrhythmias, abnormal ECG, syncope, cardiac chest pain, or history of heart attack or heart failure. For males, > 450 msec. For females QTc > 470 msec (using Fridericia correction formula).
  8. Has a history of drug/alcohol overdose as judged by the Investigator.
  9. Has alcohol breathalyzer > 0% at screening.
  10. Has a current opioid or benzodiazepine use disorder of any severity or use of these substances or alcohol in amounts that would increase risk of receiving oxazepam as part of EMB-001 or has received psychotherapy or behavioral treatments potentially impacting symptoms of depression, anxiety, or nicotine withdrawal within 30 days of screening, or during the study.
  11. Has history of mental illness that, in the opinion of the investigator, may interfere with subject safety or data integrity.
  12. Taking antidepressants, CNS or psychoactive medications (e.g., antipsychotics, benzodiazepines, hypnotics) or medications that prolong QTc within the last 30 days of screen or during study.
  13. Use of any of these products in the past 30 days:

    1. Illegal drugs (or if the urine drug screen is positive for cocaine, THC, amphetamines, methamphetamines, MDMA (Ecstasy), phencyclidine, benzodiazepines, barbiturates, or opiates at screening);
    2. Experimental () drugs or biologic;
    3. Chronic opiate use;
    4. Biotin products (Vitamin B7 or B8, Vitamin H, or coenzyme R).
  14. Use of including:

    1. Oral glucocorticoids within 90 days of screen or during study;
    2. Inhaled glucocorticoids within 90 days of screen or during study;
    3. Topical glucocorticoids within 7 days of screen or during the study (except when applied to a small body surface area);
    4. Joint injection within 90 days of screening or during the study.
  15. Donation of any blood components within 84 days of screening or during the study or loss of blood ≥ 400 mL within 84 days of screen.
  16. Use of smokeless tobacco (chewing tobacco, snuff), cigars (except for cigarillos), pipes, hookah, e-cigarettes, nicotine replacement therapy or other smoking cessation treatments within 14 days of enrollment.
  17. Pregnant or nursing (by self-report) or has a positive pregnancy test.
  18. Female subjects must be of non-. Evidence of non-childbearing potential includes documented surgical sterilization (hysterectomy or bilateral oophorectomy) or being . Postmenopausal is defined clinically as 12 months of amenorrhea in a woman over 45 years of age in the absence of other biological or physiological cause. In addition, women must have a documented serum follicle stimulating hormone (FSH) level > 40 mIU/mL during the Screening Period.
  19. Known to or intolerance of oxazepam, metyrapone, or any benzodiazepine, or severe hypersensitivity reaction (e.g., angioedema) to any drug.
  20. Treatment with an investigational drug or biologic within the 30 days preceding the first dose of study medication or plans to take another investigational drug or biologic within 30 days of study completion (including the follow-up visit).
  21. Enrollment requirements met.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    EMB-001

    EMB-001 will be administered utilizing capsules which contain 240 mg of metyrapone and 8 mg of oxazepam (240/8 mg). Subjects will be prescribed 3 capsules (total of 720 mg metyrapone and 24 mg oxazepam) taken twice daily for a total of 12 weeks. After week 12, or if indicated and possibly for a subject who is being discontinued early, subjects will take one capsule of EMB-001, 240/8 mg, twice a day for one additional week (taper dose).

    Drug: EMB-01

Interventions

  • DrugEMB-01

    EMB-001 is a proprietary combination of metyrapone (a cortisol synthesis inhibitor) and oxazepam (a short to medium acting benzodiazepine).

    Also known as: metyrapone, oxazepam

06

What researchers measure

Primary outcomes

  1. Smoking Abstinence

    Participant self-report of no cigarette smoking (not even a puff).

    Time frame: Weeks 9 through 12

  2. Smoking Abstinence

    Participant self-report of no cigarette smoking (not even a puff).

    Time frame: 6 month follow-up

  3. Smoking Abstinence

    Expired air CO reading of less than 5 ppm

    Time frame: Week 12

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2021 (actual). Primary completion is estimated for Dec 2021, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2020
First posted
Apr 30, 2021
StartActual
May 19, 2021
Primary completionEst.
Dec 31, 2021
CompletionEst.
Dec 31, 2021
Last update
May 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04868253
Lead sponsor
Rose Research Center, LLC
Collaborators
Foundation for a Smoke Free World INC, Embera NeuroTherapeutics, Inc.
Responsible party
Sponsor
First posted
Apr 30, 2021
Start date
May 19, 2021
Primary completion
Dec 31, 2021 (estimated)
Completion
Dec 31, 2021 (estimated)
Last update
May 28, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bafisontamab

Start the discussion